We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.05 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
From Apr 2019 to Apr 2024
TIDMRENE
RNS Number : 3426T
ReNeuron Group plc
11 October 2017
11 October 2017 AIM: RENE
ReNeuron Group plc
Director/PDMR Interest in Shares and Share Options
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that, on 9 October 2017, the following grants made on 11 September 2017 under the Company's Long Term Incentive Plan (LTIP) were deemed accepted by the relevant Persons Discharging Managerial Responsibilities (PDMRs). Share option grants made to Directors on 11 September 2017, which were separately announced by RNS on 12 September 2017, were also deemed accepted by those Directors on 9 October 2017. Under the terms of the grants, 9 October 2017 was the final day by which grantees could decline the option granted to them on 11 September 2017.
Hot Features
Premium
Name Title Date Date Total Percentage
of grant LTIP Number shares of issued
of LTIP share of LTIP over shares
share options share which under
options accepted options options option
granted are
& accepted held
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
Randolph 11 Sept 9 Oct
Corteling Head of Research 17 17 3,000,000 12,604,041 0.40%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
VP Development
& General
Sharon Manager - 11 Sept 9 Oct
Grimster Wales 17 17 5,750,000 19,658,334 0.62%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
John Hawkins Financial 11 Sept 9 Oct
(i) Controller 17 17 400,000 1,600,000 0.05%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
Julian Chief Medical 11 Sept 9 Oct
Howell Officer 17 17 5,566,667 21,474,243 0.68%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
Head of Regulatory 11 Sept 9 Oct
Shaun Stapleton Affairs 17 17 4,533,333 17,461,363 0.55%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
Chief Scientific 11 Sept 9 Oct
John Sinden Officer 17 17 2,983,333 21,599,743 0.68%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
The LTIP awards are share options granted at nominal value and are subject to a three-year holding period, exercisable from the third anniversary of the award. The options are exercisable subject to the achievement of the following performance conditions:
1) When the first patient is administered with a ReNeuron cell therapy in an eighth clinical trial, one third of the options will vest.
2) When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.
3) If the Total Shareholder Return (TSR) of the Company meets or exceeds that of the FTSE AIM Healthcare Index in any given three year period from the date of grant, one third of the options will vest.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.
(i) The grant to Mr Hawkins was made under the Company's Employee Share Option Plan and is exercisable subject to achievement of performance conditions (1) and (2) above, with 50% of the options vesting in each case.
SENQUIRIES:
ReNeuron +44 (0)20 3819 8400 Olav Hellebø , Chief Executive Officer Michael Hunt, Chief Financial Officer Buchanan +44 (0) 20 7466 5000 Mark Court, Sophie Cowles, Stephanie Watson Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600 Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000 Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Randolph Corteling
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Head of Research
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 3,000,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
(Disclosure in relation to share options granted and accepted by Directors and PDMRs)
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Sharon Grimster
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status VP Development & General Manager
- Wales
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 5,750,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name John Hawkins
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Financial Controller
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 400,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Julian Howell
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Chief Medical Officer
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 5,566,667
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Shaun Stapleton
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Head of Regulatory Affairs
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 4,533,333
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name John Sinden
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Chief Scientific Officer
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 2,983,333
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Olav Hellebo
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Chief Executive Officer
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 9,766,667
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Michael Hunt
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Chief Financial Officer
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 6,800,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name John Berriman
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Chairman
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Simon Cartmell
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Tim Corn
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Claudia D'Augusta
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Chris Evans
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Mike Owen
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAAEFFAPXFFF
(END) Dow Jones Newswires
October 11, 2017 08:31 ET (12:31 GMT)
1 Year Reneuron Chart |
1 Month Reneuron Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
